{"id":6393,"date":"2026-02-05T08:09:52","date_gmt":"2026-02-05T14:09:52","guid":{"rendered":"https:\/\/www.vanderbilt.edu\/csb\/?p=6393"},"modified":"2026-02-19T12:19:47","modified_gmt":"2026-02-19T18:19:47","slug":"csb-research-spotlight-sanders-lab-promising-small-molecule-may-help-with-sudden-cardiac-death","status":"publish","type":"post","link":"https:\/\/www.vanderbilt.edu\/csb\/2026\/02\/05\/csb-research-spotlight-sanders-lab-promising-small-molecule-may-help-with-sudden-cardiac-death\/","title":{"rendered":"CSB Research Spotlight: Sanders Lab\u2014Promising small molecule may help with sudden cardiac death"},"content":{"rendered":"
Long QT syndrome (LQTS) is a hereditary or acquired cardiac disorder that affects the electrical system of the heart, which causes a delay in the heart\u2019s repolarization or reset time. This delay means the heart takes longer to reset between beats.<\/p>\n
LQTS is a fatal disorder linked to syncope, arrhythmia, and cardiac arrest. Type 1 Long QT syndrome (LQT1) accounts for close to half of congenital LQTS and is caused by loss-of-function mutations in the voltage-gated potassium channel KCNQ1.<\/p>\n
The Sanders lab recently investigated whether a small molecule could help these channel proteins work better, with a goal that one day it might help treat long QT syndrome.<\/p>\n